摘要
目的探讨吉西他滨与LY294002单药或联合应用对人类胰腺癌细胞BxPe-3和MiaPaCa-2增殖和凋亡的影响。方法MTr法检测细胞增殖,AnnexinV—FITC法检测细胞凋亡。结果吉西他滨与LY294002对两株细胞增殖均有抑制作用,且作用随药物浓度增加而增强,各组用药剂量的对数值与细胞生存率之间呈负相关(r〈-0.95,P〈0.01);吉西他滨与LY294002对BxPe-3细胞的抑制作用明显强于对MiaPaCa-2细胞作用(P〈0.05)。BxPe-3和MiaPaCa-2细胞对吉西他滨的IC50分别为(10.07±1.83)、(36.45±2.71)斗mnl/L(P〈0.05),对LY294002的‰分别为(7.84±1.48)、(17.89±1.98)μmol/L(P〈0.05)。吉西他滨与LY294002可诱导两株细胞凋亡(P〈0.01),吉西他滨与LY294002同时或序贯应用,均表现出对两株细胞凋亡的促进作用,其中以LY294002和吉西他滨同时给药组作用最为显著(P〈0.05),序贯组药物应用的先后顺序并未对细胞凋亡率产生影响(P〉0.05)。结论吉西他滨和LY294002体外可显著抑制胰腺癌细胞增殖,二者同时应用能显著促进其凋亡。
Objective To investigate the effects of gemcetabine and LY294002 monotherapy or combination on the proliferation and poptosis of pancreatic cancer cell lines BxPc-3 and MiaPaCa-2. Methods Cell proliferation and poptosis were detected by MTr and Annexin V-FITC, respectively. Results Both gemcetabine and LY294002 could inhabit the proliferation of the two cell lines. Their inhibitory effects were increased accompanied with increased drug concentrations and the cell survival rates was negatively correlated with logarithmic of the drug concentrations (r〈-0.95, P〈0.01). The inhibitory effects of gemcetabine and LY294002 to the BxPc-3 proliferation were significantly stronger than to the MiaPaCa-2 (P〈0.05).For BxPc-3 and MiaPaCa-2, the IC5o of gemcetabine were (10.07±1.83), (36.45±2.71) μmol/L(P〈0.05), and the IC50 of LY294002 were (7.84±1.48), (17.89±1.98) μmol/L(P〈0.05), respectively. Gemcetabine and LY294002 could induce cell apoptosis (P〈0.01). Though both the concurrent or consecutive use of these two drugs could promote cell apoptosis, the effect of the concurrent group was significantly stronger (P〈0.05). The order of these two drugs in the concurrent group had no significant influence on their effects (P〉0.05). Conclusion Both gemcetabine and LY294002 could inhibit the proliferation of pancreatic cancer cell lines. Their concurrent application shows a significant inhibitory effect on the cell apoptosis.
出处
《肿瘤研究与临床》
CAS
2012年第6期389-391,394,共4页
Cancer Research and Clinic
基金
吴阶平医学基金会癌症靶向治疗研究基金(3206740-10016)